Risk factors
Passage BIO (PASG) risk factors
Item 1A of every Passage BIO, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
64 risks, 3 new, 4 dropped, 8 reworded since the prior year. Passage Bio added risks regarding accelerated FDA approvals, healthcare fraud laws, and privacy regulations. Budget Control Act Medicare cuts were extended through 2032.
Filed Mar 03, 2026 - FY2024 10-K risk factors
65 risks. Passage Bio faces typical pre-revenue biotech risks dominated by its sole clinical candidate PBFT02 and novel gene therapy technology. Reliance on third-party manufacturers like Catalent and licensors like Penn creates significant operational dependencies. Intellectual property protection and raising additional capital are critical to future survival.
Filed Mar 04, 2025